Recent Finacing
Recent Raise
Osteros Biomedica develops MBC‑11, a bisphosphonate bone‑targeting cytotoxic conjugate for multiple myeloma, osteosarcoma, and metastatic bone lesions and is preparing proof‑of‑concept clinical trials in Russia.
Recent Investors
Funding round
Investor